Animal and Cell Models for type II diabetes and their use

Alan Hart; Helena Edlund; N Baeza; A Apelqvist

Animal and Cell Models for type II diabetes and their use

Alan Hart (Inventor), Helena Edlund (Inventor), N Baeza (Inventor), A Apelqvist (Inventor)

Royal (Dick) School of Veterinary Studies

Research output: Patent

Abstract / Description of output

A transgenic diabetes type II model laboratory animal is disclosed which comprises beta-cells expressing a dominant negative form (dnFGFR1c) of FGFR1c. Also disclosed is the use of the Ipf1/Pdx1 promoter for controlling expression of FGFR1c; beta-cells in which the expression of PC1/3 is down-regulated or absent or which are competent to express a dominant negative form (dnFGFR1c) of FGFR1c; mature beta-cells incompetent to express Glut2 or in which the processing of proinsulin is substantially impaired; a method of preventing or treating type II diabetes.

Original language	English
Patent number	WO/2001/076361
IPC	PCT/SE2001/000783
Publication status	Published - 18 Oct 2001

Cite this

@misc{cc44afb2fa2444f49a12ed3bc42707e9,

title = "Animal and Cell Models for type II diabetes and their use",

abstract = "A transgenic diabetes type II model laboratory animal is disclosed which comprises beta-cells expressing a dominant negative form (dnFGFR1c) of FGFR1c. Also disclosed is the use of the Ipf1/Pdx1 promoter for controlling expression of FGFR1c; beta-cells in which the expression of PC1/3 is down-regulated or absent or which are competent to express a dominant negative form (dnFGFR1c) of FGFR1c; mature beta-cells incompetent to express Glut2 or in which the processing of proinsulin is substantially impaired; a method of preventing or treating type II diabetes.",

author = "Alan Hart and Helena Edlund and N Baeza and A Apelqvist",

year = "2001",

month = oct,

day = "18",

language = "English",

type = "Patent",

note = "WO/2001/076361; PCT/SE2001/000783",

}

TY - PAT

T1 - Animal and Cell Models for type II diabetes and their use

AU - Hart, Alan

AU - Edlund, Helena

AU - Baeza, N

AU - Apelqvist, A

PY - 2001/10/18

Y1 - 2001/10/18

N2 - A transgenic diabetes type II model laboratory animal is disclosed which comprises beta-cells expressing a dominant negative form (dnFGFR1c) of FGFR1c. Also disclosed is the use of the Ipf1/Pdx1 promoter for controlling expression of FGFR1c; beta-cells in which the expression of PC1/3 is down-regulated or absent or which are competent to express a dominant negative form (dnFGFR1c) of FGFR1c; mature beta-cells incompetent to express Glut2 or in which the processing of proinsulin is substantially impaired; a method of preventing or treating type II diabetes.

AB - A transgenic diabetes type II model laboratory animal is disclosed which comprises beta-cells expressing a dominant negative form (dnFGFR1c) of FGFR1c. Also disclosed is the use of the Ipf1/Pdx1 promoter for controlling expression of FGFR1c; beta-cells in which the expression of PC1/3 is down-regulated or absent or which are competent to express a dominant negative form (dnFGFR1c) of FGFR1c; mature beta-cells incompetent to express Glut2 or in which the processing of proinsulin is substantially impaired; a method of preventing or treating type II diabetes.

M3 - Patent

M1 - WO/2001/076361

ER -

Animal and Cell Models for type II diabetes and their use

Abstract / Description of output

Fingerprint

Cite this